Increased pulmonary epithelial permeability in systemic sclerosis is associated with enhanced cutaneous nerve growth factor expression

European Journal of Internal Medicine

Volumn 11, Issue 3, 2000, Pages 156-160

  Piga, M ^a   Passiu, G ^b   Carta, P ^a   Satta, L ^a   Cherchi, V ^a   Pala, R ^b   Sanna, G ^b   Cauli, A ^b   Tuveri, M A ^c   Aloe, L ^c   Mathieu, A ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Ctr Systemic Rheum Dis Dept M   (Italy)

^c CNR   (Italy)

Author keywords

Connective tissue diseases; Nerve growth factor; Pulmonary epithelial permeability; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

NERVE GROWTH FACTOR;

ADULT; AGED; ARTICLE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MALE; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS;

EID: 0034042386     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(00)00084-4     Document Type: Article

References (28)

1. Sackner M., Akgun N., Kimbel P., Lewis D. The pathophysiology of scleroderma involving the heart and respiratory system. Ann Intern Med. 60:1964;611-630.
2. McCarthy D., Baragar F., Dingra S., et al. The lungs in systemic sclerosis (scleroderma): a review and new information. Semin Arthritis Rheum. 17:1988;271-283.
3. Wilson R., Rodnan G., Robin E. An early pulmonary physiologic abnormality in progressive systemic sclerosis (diffuse scleroderma). Am J Med. 36:1964;361-369.
4. Steen V., Owens G., Fino G., Rodnan G., Medsger D. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 28:1985;759-767.
5. Schneider P., Wise R., Hochberg M., Wigley F. Serial pulmonary function in systemic sclerosis. Am J Med. 73:1982;384-394.
6. Owens G.R., Fino G.J., Herbert D.L., et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest. 84:1983;546-550.
7. Dujic Z., Eterovic D., Tocilj J., Andjelinovic D. Increase of pulmonary diffusing capacity in systemic sclerosis. Br J Rheumatol. 33:1994;437-441.
8. Oberdoster G., Utell M., Morrow P., Hyde R., Weber D. Bronchial and alveolar absorption of inhaled 99mTc-DTPA. Am Rev Respir Dis. 134:1986;944-950.
9. Coates G., O'Brodovich H. Measurement of pulmonary epithelial permeability with 99mTc-DTPA aerosol. Semin Nucl Med. 16:1986;275-284.
10. Jones J.G., Minty B.D., Lawler P., Hulands G., Crawley J.C., Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1:1980;66-68.
11. Rinderknect J., Shapiro L., Krauthammer M., et al. Accelerated clearance of small solutes from the lungs in interstitial lung disease. Am Rev Respir Dis. 121:1980;105-117.
12. Chinet T., Dusser D., Labrune S., Collignon M., Chretien J., Huchon G. Lung function declines in patients with pulmonary sarcoidosis and increased respiratory epithelial permeability to 99m Tc-DTPA. Am Rev Respir Dis. 141:1990;445-449.
13. Susskind H., Weber D., Volkow N., Hitzemann R. Increased lung permeability following long-term use of free-base cocaine (crack). Chest. 100:1991;903-909.
14. Ugur O., Caner B., Balbay M., et al. Bleomycin lung toxicity detected by Tc-99m diethylenetriaminepentaceticacid aerosol scintigraphy. Eur J Nucl Med. 20:1993;114-118.
15. Fanti S., de Fabritiis A., Aloisi D., et al. Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med. 35:1994;1933-1936.
16. Staub N., Hyde R., Crandall E. Workshop on techniques to evaluate lung alveolar-microvascular injury. Am Rev Resp Dis. 141:1990;1071-1077.
17. Aloe L., Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with nerve growth factor. Brain Res. 133:1977;358-366.
18. Pearce F., Thompson H. Some characteristics of histamine secretion from rats peritoneal mast cells stimulated with nerve growth factor. J Physiol. 372:1986;379-393.
19. Hawkins R., Claman H., Clark R., Steigerwald J. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med. 102:1985;182-186.
20. Tuveri M., Passiu G., Mathieu A., Aloe L. Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. Clin Exp Rheumatol. 11:1993;319-322.
21. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:1980;581-590.
22. Standardization of spirometry - 1987 update. Am Rev Respir Dis. 136:1987;1285-1298.
23. Quanier P. Standardized lung function testing. Report working party standardization of lung function tests. European Community for Coal and Steel. Bull Eur Physiopathol Respir. 5:1983;1-95.
24. Remy-Jardin M., Remy J., Wallaert B., Bataille D., Hatron P.-Y. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests and brochoalveolar lavage. Radiology. 188:1993;499-506.
25. Aloe L. Adrenalectomy decreases nerve growth factor in young adult rat hippocampus. Proc Natl Acad Sci USA. 86:1989;5636-5640.
26. Jones J., Minty B., Royston D. The physiology of leaky lungs. Br J Anaesth. 54:1982;705-721.
27. Harrison N., Myers A., Corrin B., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 144:1991;706-713.
28. Pignone A., Scaletti C., Matucci-Cerinic M., et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol. 16:1998;527-532.